vs
Side-by-side financial comparison of Arteris, Inc. (AIP) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Intellia Therapeutics, Inc. is the larger business by last-quarter revenue ($23.0M vs $20.1M, roughly 1.1× Arteris, Inc.). Arteris, Inc. runs the higher net margin — -42.2% vs -416.2%, a 373.9% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 30.0%). Arteris, Inc. produced more free cash flow last quarter ($3.0M vs $-69.4M). Over the past eight quarters, Arteris, Inc.'s revenue compounded faster (24.7% CAGR vs -10.8%).
Arteris, Inc. is a multinational technology company headquartered in Campbell, California. It develops the network-on-chip (NoC) IP and system-on-chip (SoC) integration automation software that is used to create semiconductor chip and chiplet designs for a variety of devices, particularly in automotive electronics, artificial intelligence, machine learning, enterprise computing, communications, consumer, industrial, and aerospace & defense markets. The company specializes in the development a...
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
AIP vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.1M | $23.0M |
| Net Profit | $-8.5M | $-95.8M |
| Gross Margin | 90.8% | — |
| Operating Margin | -42.0% | -428.9% |
| Net Margin | -42.2% | -416.2% |
| Revenue YoY | 30.0% | 78.8% |
| Net Profit YoY | -3.7% | 25.7% |
| EPS (diluted) | $-0.19 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.1M | $23.0M | ||
| Q3 25 | $17.4M | $13.8M | ||
| Q2 25 | $16.5M | $14.2M | ||
| Q1 25 | $16.5M | $16.6M | ||
| Q4 24 | $15.5M | $12.9M | ||
| Q3 24 | $14.7M | $9.1M | ||
| Q2 24 | $14.6M | $7.0M | ||
| Q1 24 | $12.9M | $28.9M |
| Q4 25 | $-8.5M | $-95.8M | ||
| Q3 25 | $-9.0M | $-101.3M | ||
| Q2 25 | $-9.1M | $-101.3M | ||
| Q1 25 | $-8.1M | $-114.3M | ||
| Q4 24 | $-8.2M | $-128.9M | ||
| Q3 24 | $-7.7M | $-135.7M | ||
| Q2 24 | $-8.3M | $-147.0M | ||
| Q1 24 | $-9.4M | $-107.4M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 89.9% | — | ||
| Q2 25 | 89.4% | — | ||
| Q1 25 | 90.8% | — | ||
| Q4 24 | 89.8% | — | ||
| Q3 24 | 90.1% | — | ||
| Q2 24 | 90.0% | — | ||
| Q1 24 | 88.7% | — |
| Q4 25 | -42.0% | -428.9% | ||
| Q3 25 | -50.1% | -808.9% | ||
| Q2 25 | -50.0% | -772.2% | ||
| Q1 25 | -46.6% | -726.6% | ||
| Q4 24 | -45.9% | -1059.9% | ||
| Q3 24 | -53.8% | -1589.0% | ||
| Q2 24 | -51.1% | -1998.6% | ||
| Q1 24 | -70.5% | -394.0% |
| Q4 25 | -42.2% | -416.2% | ||
| Q3 25 | -51.6% | -735.2% | ||
| Q2 25 | -55.3% | -710.8% | ||
| Q1 25 | -49.1% | -687.6% | ||
| Q4 24 | -53.0% | -1001.2% | ||
| Q3 24 | -52.2% | -1489.5% | ||
| Q2 24 | -57.2% | -2112.6% | ||
| Q1 24 | -72.6% | -371.3% |
| Q4 25 | $-0.19 | $-0.81 | ||
| Q3 25 | $-0.21 | $-0.92 | ||
| Q2 25 | $-0.22 | $-0.98 | ||
| Q1 25 | $-0.20 | $-1.10 | ||
| Q4 24 | $-0.19 | $-1.27 | ||
| Q3 24 | $-0.20 | $-1.34 | ||
| Q2 24 | $-0.22 | $-1.52 | ||
| Q1 24 | $-0.25 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $33.9M | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-14.6M | $671.4M |
| Total Assets | $115.0M | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $33.9M | $449.9M | ||
| Q3 25 | $39.0M | $511.0M | ||
| Q2 25 | $38.0M | $459.7M | ||
| Q1 25 | $42.3M | $503.7M | ||
| Q4 24 | $43.8M | $601.5M | ||
| Q3 24 | $48.7M | $658.1M | ||
| Q2 24 | $45.8M | $691.1M | ||
| Q1 24 | $44.8M | $791.3M |
| Q4 25 | $-14.6M | $671.4M | ||
| Q3 25 | $-11.4M | $748.4M | ||
| Q2 25 | $-7.5M | $715.3M | ||
| Q1 25 | $-4.8M | $779.9M | ||
| Q4 24 | $-1.2M | $872.0M | ||
| Q3 24 | $2.2M | $962.6M | ||
| Q2 24 | $5.3M | $971.1M | ||
| Q1 24 | $9.5M | $1.0B |
| Q4 25 | $115.0M | $842.1M | ||
| Q3 25 | $107.7M | $925.3M | ||
| Q2 25 | $106.9M | $898.9M | ||
| Q1 25 | $98.3M | $986.2M | ||
| Q4 24 | $106.1M | $1.2B | ||
| Q3 24 | $97.7M | $1.2B | ||
| Q2 24 | $96.4M | $1.2B | ||
| Q1 24 | $101.4M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.2M | $-69.3M |
| Free Cash FlowOCF − Capex | $3.0M | $-69.4M |
| FCF MarginFCF / Revenue | 15.1% | -301.6% |
| Capex IntensityCapex / Revenue | 0.7% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.3M | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.2M | $-69.3M | ||
| Q3 25 | $3.2M | $-76.9M | ||
| Q2 25 | $-2.5M | $-99.6M | ||
| Q1 25 | $2.9M | $-148.9M | ||
| Q4 24 | $-2.6M | $-85.2M | ||
| Q3 24 | $1.1M | $-84.8M | ||
| Q2 24 | $311.0K | $-58.2M | ||
| Q1 24 | $477.0K | $-120.7M |
| Q4 25 | $3.0M | $-69.4M | ||
| Q3 25 | $2.5M | $-76.9M | ||
| Q2 25 | $-2.8M | $-99.9M | ||
| Q1 25 | $2.7M | $-149.7M | ||
| Q4 24 | $-2.7M | $-86.2M | ||
| Q3 24 | $1.1M | $-86.1M | ||
| Q2 24 | $264.0K | $-59.2M | ||
| Q1 24 | $281.0K | $-123.2M |
| Q4 25 | 15.1% | -301.6% | ||
| Q3 25 | 14.2% | -558.2% | ||
| Q2 25 | -17.2% | -701.0% | ||
| Q1 25 | 16.2% | -900.1% | ||
| Q4 24 | -17.3% | -669.4% | ||
| Q3 24 | 7.4% | -945.2% | ||
| Q2 24 | 1.8% | -850.9% | ||
| Q1 24 | 2.2% | -425.7% |
| Q4 25 | 0.7% | 0.5% | ||
| Q3 25 | 4.1% | 0.2% | ||
| Q2 25 | 2.2% | 1.7% | ||
| Q1 25 | 1.1% | 4.4% | ||
| Q4 24 | 0.3% | 7.6% | ||
| Q3 24 | 0.2% | 14.0% | ||
| Q2 24 | 0.3% | 14.5% | ||
| Q1 24 | 1.5% | 8.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AIP
| License And Maintenance | $17.5M | 87% |
| Variable Royalties And Other | $2.6M | 13% |
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
